FDA Clearance Tracker · DEN130012
FERRISCAN R2-MRI ANALYSIS SYSTEM
Last checked: Nov 20, 2026Latest source record: Jan 23, 2013 (this decision)Source: openFDAMethods & limitations
Decided
Jan 23, 2013
De Novo granted
Time to decision
21 days
Received Jan 2, 2013. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Direct
Device class
Class II
The decision
- FDA number
- DEN130012
- Device name
- FERRISCAN R2-MRI ANALYSIS SYSTEM
- Applicant location
- Irvine, CA
- Received
- Jan 2, 2013
- Decided
- Jan 23, 2013
- Decision
- De Novo granted
- Submission type
- Direct
Device type
- Device class
- Class II
- Regulation
- 21 CFR 892.1001
- Specialty
- Radiology & Imaging
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for DEN130012
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for Resonance Health Analysis Services Pty, Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- HepaFatSmart (V2.0.0)510(k)
K231459 · Decided Jun 20, 2023 · 32 days after receipt
Device type: System, Nuclear Magnetic Resonance Imaging (LNH) · Radiology & Imaging
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.